Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma
| Autor: | Hideki Fujii, Akishi Ooi, Mitsuhiko Hanawa, Hidemitsu Sugai, Kosaku Mimura, Koji Kono, F Mitsui, Naoto Miyagawa |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Male
Cancer Research Pathology medicine.medical_specialty Esophageal Neoplasms HER-2/neu Receptor ErbB-2 T-Lymphocytes Human leukocyte antigen Biology HercepTest FISH HLA Antigens Gene duplication Carcinoma medicine Humans Molecular Diagnostics Survival rate In Situ Hybridization Fluorescence Aged Aged 80 and over medicine.diagnostic_test Reverse Transcriptase Polymerase Chain Reaction Gene Expression Profiling Vaccination Gene Amplification Cancer Middle Aged medicine.disease Immunohistochemistry Survival Analysis HLA Gene expression profiling Haplotypes Oncology Carcinoma Squamous Cell Cancer research Female Immunotherapy Follow-Up Studies Fluorescence in situ hybridization |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| DOI: | 10.1038/sj.bjc.6602499 |
| Popis: | The utilisation of antitumour T cells induced by cancer vaccination with HER-2 peptides or antibodies (Herceptin) against HER-2, as immunotherapy for oesophageal cancer, is a novel and attractive approach. It is important to clarify the frequencies of HER-2 expression and gene amplification in patients with oesophageal squamous cell carcinoma (SCC) and to evaluate the relationship between HER-2 status and HLA haplotype, since the candidates for HER-2 peptide-based vaccination are restricted to a certain HLA haplotype. We determined the frequency of HER-2 expression using the HercepTest™ for immunohistochemistry and HER-2 gene amplification by fluorescence in situ hybridisation (FISH) assay in oesophageal SCC (n=66). HER-2-positive tumours (1+/2+/3+) analysed by a HercepTest were observed in 30.3% of all the patients and HER-2 gene amplification evaluated by FISH was observed in 11.0% of all the patients, in which all HercepTest (3+) tumours were found to have gene amplification and three of six moderately positive (2+) tumours showed gene amplification. Furthermore, HER-2-positive cells were present more diffusely and were larger within each tumour in the patients who were HercepTest 3+ than those who were HercepTest 1+. Moreover, the survival rate in HER-2-positive group was significantly worse than that in HER-2-negative group. Also, the survival rate in the patients with HER-2 gene amplification was significantly worse than that without HER-2 gene amplification. In addition, oesophageal SCC patients with both HLA-A24-positive and HER-2-positive tumours (1+/2+/3+) accounted for 26% of these cases, and both HLA-A2- and HER-2-positive tumours accounted for 18% of them. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|